Who and Where

Who is looking at NAC in COVID?

Determination of efficacy of N-Acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease


ClinicalTrials.gov ID NCT04419025


Application submission to CHA IRB May 1, 2020

Approval August 7, 2020

Enrollment September 30, 2020

Principal Investigator (PI)

Melisa Lai-Becker MD

Enrollment Eligibility (updated 12/8/2020)

Age >= 18 years, not pregnant at time of enrollment; known or suspect COVID-19 disease AND one or more of any influenza-like symptom, including:

  • diarrhea

  • vomiting

  • fever (subjective or measured)

  • chills

  • myalgias

  • fatigue

  • sore throat

  • headache

  • cough

  • nasal/sinus congestion or rhinorrhea

  • shortness of breath

  • chest pain

John Adams MD MPH Internist and Pediatrician, CHA Acute Care/Respiratory Clinic project leader; Instructor, Harvard Medical School

Kerry Blomquist RN Emergency Nurse, CHA Everett Hospital

Pieter Cohen MD Internist, Primary Care, CHA; Associate Professor, Harvard Medical School

Julie Devito PA-C Physician Assistant, CHA Department of Emergency Medicine

Jessica Early MD Family Medicine Physician, Hospitalist, CHA; Assistant Professor, Tufts University School of Medicine

Ellie Grossman MD MPH Primary Care Lead for Behavioral Health Integration; Instructor, Harvard Medical School

Lara Hall MD Family Medicine Physician; CHA Acute Care/Respiratory Clinic COVID-19 Clinical Lead

Rachel Hathaway MD Hospital Medicine Physician. Director, HMS Medicine Sub Internship; Director, CHA Internal Medicine Resident Evaluation; Instructor, Harvard Medical School

Janice N. John PA-C MHS MHCDS Medical Director, CHA Acute Care/Respiratory Clinic; Chief PA, Primary Care; Associate Medical Director, Assembly Square Primary Care

Duncan Kuhn MD Pulmonary & Critical Care Physician, CHA; Pulmonary & Critical Care Physician, North Shore Medical Center (Salem MA); Infectious Diseases specialist; Instructor, Harvard Medical School

Melisa Lai-Becker MD Chief, Everett Emergency Department; Director, Division of Medical Toxicology; Medical Toxicologist, Regional Center for Poison Control and Prevention Serving MA & RI; Medical Toxicologist, Boston Children's Hospital; Assistant Professor, Harvard Medical School

Anna Rabkina MD Internist, Primary Care, CHA and Lynn Community Health Center; Team Leader, Market Square Family Health Services; Instructor, Harvard Medical School

Mary Regan PharmD Director, Clinical and Academic Pharmacy Services; Senior Clinical Pharmacist Specialist – Critical Care; Administrator, ACPE-Accredited CPE Programming

Neha Sandeep PA-C Family Medicine PA, CHA Acute Care/Respiratory Clinic and Primary Care, CHA

Yamini Saravanan MD MHS Clerkship Director, HMS Primary Care; Clerkship Director, HMS Internal Medicine Clerkship; Associate Director, HMS Primary Care Experience; Instructor, Harvard Medical School

Alix Schrager MD Senior resident (PGY3), Harvard Internal Medicine Residency at CHA; Clinical Fellow in Medicine, Harvard Medical School

Anna Shapiro PA-C Physician Assistant, CHA Primary Care

Linda Shipton MD Infectious Diseases specialist, CHA and Spaulding Rehabilitation Center; Medical Director, Tuberculosis Program, MA DPH, CHA; Assistant Professor, Harvard Medical School

Tom Seufert MD Emergency Physician; Associate Director of Clinical Informatics; Director of Emergency Informatics; Instructor, Harvard Medical School

Lisa Yasi RRT Respiratory Therapist, CHA Everett

Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

ClinicalTrials.gov Identifier: NCT04545008

Prisma Health and Clemson University

A Study of N-acetylcysteine in Patients With COVID-19 Infection

ClinicalTrials.gov Identifier: NCT04374461

Memorial Sloan Kettering Cancer Center

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients (PRANA)

ClinicalTrials.gov Identifier: NCT04458298

Ashvattha Therapeutics (formerly Orpheris, Inc.)

Inflammatory Regulation Effect of NAC on COVID-19 Treatment (INFECT-19)

ClinicalTrials.gov Identifier: NCT04455243

King Saud University, Saudi Arabia

Clinical Application of Methylene Blue for Treatment of Covid-19 Patients (Covid-19)

ClinicalTrials.gov Identifier: NCT04370288

Mashhad University of Medical Sciences, Iran

Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu

ClinicalTrials.gov Identifier: NCT04279197

ShuGuang Hospital, Shanghai, China

Antioxidant Therapy for COVID-19 Study (GSHSOD-COVID)

ClinicalTrials.gov Identifier: NCT04466657

Obafemi Awolowo University, Nigeria